Partnership combines large-scale real-world imaging and clinical data with advanced AI capabilities to accelerate biomarker development, real-world evi...
BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identi...
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.)...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena admini...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery...
Bavarian Nordic A/S announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikung...
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise ...
As demand grows for increasingly sophisticated DNA and RNA-based therapies, the industry's focus is expanding beyond scientific discovery to the infrastruc...
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for...
Hartwig to adopt Ultima Genomics' UG200 sequencing system to accelerate implementation of whole-genome-based clinical genomics workflows on Solaris 2.0 t...
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are n...
Zymo Research, a global leader in genomics tools, announced the launch of Zymo Services, a dedicated portfolio of end-to-end next-generation sequencing (...
© 2026 Biopharma Boardroom. All Rights Reserved.
